Pharma BD Deal Intelligence
Matrix became the backbone of Mylan's global API/manufacturing platform for 15+ years, but chronic FDA quality problems and an eventual 2023-24 divestiture (sold back to the founder's family) mean the long-run outcome is mixed, not a clean win.
Full analysis, sources & comparables →This is an extremely complementary transaction that accomplishes a number of Mylan's key objectives. - Robert J. Coury, Mylan CEO. Matrix's Executive Chairman…
We think the deal Mylan announced today may turn out to be both expensive and problematic for the company. - Banc of America Securities analyst David W. Maris,…
Matrix gave Mylan access to China, India and African markets, and the deal was characterized as the largest-ever takeover in the Indian pharma industry at the…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Indian generics/API; up to 71.5% controlling interest at INR 306/share
Matrix became the backbone of Mylan's global API/manufacturing platform for 15+ years, but chronic FDA quality problems and an eventual 2023-24 divestiture (sold back to the founder's family) mean the long-run outcome is mixed, not a clean win.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mylan Laboratories Inc. / Matrix Laboratories Limited (this deal) | 2006 | $736M | 66 |
| Mylan Laboratories Inc. / Merck Generics (Merck KGaA) | 2007 | $6.7B | 81 |
| Mylan Laboratories Inc. / Matrix Laboratories Limited | 2005 | $736M | 39 |
| Mylan Laboratories Inc. / King Pharmaceuticals Inc. | 2004 | $4.0B | — |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses | 2006 | $460M | 83 |